While artificial intelligence propels innovation in biotech, emerging challenges require scrutiny. The FDA's AI tool, Elsa, has been reported to generate fabricated studies and misrepresent data, raising concerns about reliability. Conversely, new AI methodologies advance molecular discovery, exemplified by AI-engineered T-cell immunotherapies and AI models for medical imaging analysis. EMBL's $40 million funding supports expansive biomedical AI research. These developments underscore the dual nature of AI as a transformative yet unrefined force necessitating cautious integration within bioscience applications.